100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R01CA185457
Award Date
9/25/14
Completion Date
4/30/19
Dollars Obligated
$3.8M
Overview
Activity
12
Transactions
12
Subawards
Similar Awards
Federal Agency
National Cancer Institute
Awardee
Curadel LLC (ZWWLNUMQH996)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Update #1
Update #2
(PQC-5) ZWITTERIONIC NIR/ZR-89 AGENTS FOR PROSTATE CANCER STAGING AND TREATMENT
Posted 9/25/14
5
1
2
3
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
(PQC-5) ZWITTERIONIC NIR/ZR-89 AGENTS FOR PROSTATE CANCER STAGING AND TREATMENT - DESCRIPTION (PROVIDED BY APPLICANT): PROSTATE CANCER PRESENTS A CONUNDRUM. ON ONE HAND, THE VAST MAJORITY OF TUMORS ARE BIOLOGICALLY INDOLENT, AND LIKELY DO NOT REQUIRE TREATMENT. ON THE OTHER HAND, TUMORS FOUND TO BE LOCALLY ADVANCED DURING SURGERY REQUIRE AGGRESSIVE TREATMENT FOR CURE. EVEN WITH THIS CONUNDRUM, MOLECULAR IMAGING HAS THE POTENTIAL TO MAKE AN ENORMOUS IMPACT ON PATIENT CARE. FOR STAGING, PET/MRI COULD IDENTIFY TUMORS THAT ARE NO LONGER ORGAN-CONFINED, AND THUS SPARE MEN FROM FUTILE SURGERY. FOR MEN WHO ARE SURGICAL CANDIDATES, OPTICAL IMAGING VIA NEAR-INFRARED (NIR) FLUORESCENCE COULD PROVIDE REAL-TIME GUIDANCE DURING PROSTATE RESECTION, AND IMPORTANTLY, HIGHLIGHT AREAS OF EXTRACAPSULAR EXTENSION OR IN-TRANSIT METASTASES. TO ACHIEVE BOTH GOALS, THOUGH, A TECHNOLOGY THAT IMPROVES CANCER CELL DETECTION BY AT LEAST 100-FOLD OVER CONVENTIONAL MEANS IS REQUIRED. THE HYPOTHESIS GUIDING THIS STUDY IS THAT ZWITTERIONIC CONTRAST AGENTS AND RADIOTRACERS, DEFINED AS MOLECULES WITH ELECTRICALLY-NEUTRAL AND GEOMETRICALLY-BALANCED ALTERNATING POSITIVE AND NEGATIVE CHARGES, WILL PROVIDE LOG-LEVEL IMPROVEMENTS IN MOLECULAR IMAGING. THIS HYPOTHESIS IS BASED ON OBSERVATIONS FROM OUR GROUP USING SMALL MOLECULE, PROTEIN, AND NANOPARTICLE SYSTEMS. IN EACH CASE, ZWITTERIONIC MOLECULES EXHIBITED EXTREMELY LOW NON-SPECIFIC BINDING TO NORMAL TISSUES AND ORGANS. AND, WHEN ENGINEERED TO EXHIBIT RAPID, RENAL- ONLY CLEARANCE, UNBOUND DOSE WAS ELIMINATED COMPLETELY FROM THE BODY, RESULTING IN HIGH SBR. THE FOCUS OF OUR STUDY IS PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA), A TYPE II MEMBRANE RECEPTOR TO WHICH WE HAVE PREVIOUSLY DEVELOPED HIGH AFFINITY (2 AND 9 NM) SMALL MOLECULE TARGETING LIGANDS CALLED GPI. WE WILL CREATE ZWITTERIONIC VERSIONS OF GPI THAT HAVE BOTH OPTICAL (800 NM NIR FLUORESCENCE) AND PET (DEFEROXAMINE CHELATION OF ZR-89) FUNCTIONAL GROUPS (ZWGPI). MATHEMATICAL MODELING OF ZWGPI'S PERFORMANCE IN VIVO REVEALS THAT THE COMBINATION OF CONSTITUTIVE ENDOCYTOSIS VIA PSMA, AND THE USE OF A LONG HALF-LIFE ISOTOPE, SUCH AS ZR-89, WILL RESULT IN SBRS 100-FOLD HIGHER THAN IS CURRENTLY POSSIBLE. OR SPECIFIC AIMS INCLUDE CHEMICAL OPTIMIZATION OF ZWGPI, IN VIVO VALIDATION, CGMP MANUFACTURE UNDER 21 CFR 211/212, AND A SET OF FIRST-IN-HUMAN TRIALS IN MEN UNDERGOING PROSTATE CANCER STAGING AND RESECTION. TO ACCOMPLISH THESE AMBITIOUS AIMS, WE HAVE ASSEMBLED AN INTERNATIONAL TEAM OF EXPERTS. WE ALSO LEVERAGE A UNIQUE INFRASTRUCTURE AT BIDMC. THE NEWLY OPENED TRANSLATIONAL CANCER IMAGING FACILITY (TCIF) IS CAPABLE OF MANUFACTURING IND-ELIGIBLE OPTICAL CONTRAST AGENTS AND PET RADIOTRACERS UNDER BOTH 21 CFR 211 AND 21 CFR 212 CGMP COMPLIANCE. OF SPECIAL NOTE, ZW800-1, THE ZWITTERIONIC NIR FLUOROPHORE ON WHICH THIS STUDY IS BASED, WAS ALSO MANUFACTURED IN THE TCIF AND HAS ALREADY BEEN THROUGH THE FDA IND PROCESS. THUS THE REGULATORY PATH FOR ZWGPI IS WELL DEFINED AT THE OUTSET AND BUDGETED APPROPRIATELY IN OUR APPLICATION. COMPLETION OF OUR SPECIFIC AIMS HAS THE POTENTIAL TO REVOLUTIONIZE PROSTATE CANCER CARE BY PROVIDING IMPROVED PET/MRI STAGING AND, IF THE CHOSEN DEFINITIVE TREATMENT IS SURGERY, REAL-TIME INTRAOPERATIVE GUIDANCE.
($10k)
10/1/22
Not listed
(PQC-5) ZWITTERIONIC NIR/ZR-89 AGENTS FOR PROSTATE CANCER STAGING AND TREATMENT - DESCRIPTION (PROVIDED BY APPLICANT): PROSTATE CANCER PRESENTS A CONUNDRUM. ON ONE HAND, THE VAST MAJORITY OF TUMORS ARE BIOLOGICALLY INDOLENT, AND LIKELY DO NOT REQUIRE TREATMENT. ON THE OTHER HAND, TUMORS FOUND TO BE LOCALLY ADVANCED DURING SURGERY REQUIRE AGGRESSIVE TREATMENT FOR CURE. EVEN WITH THIS CONUNDRUM, MOLECULAR IMAGING HAS THE POTENTIAL TO MAKE AN ENORMOUS IMPACT ON PATIENT CARE. FOR STAGING, PET/MRI COULD IDENTIFY TUMORS THAT ARE NO LONGER ORGAN-CONFINED, AND THUS SPARE MEN FROM FUTILE SURGERY. FOR MEN WHO ARE SURGICAL CANDIDATES, OPTICAL IMAGING VIA NEAR-INFRARED (NIR) FLUORESCENCE COULD PROVIDE REAL-TIME GUIDANCE DURING PROSTATE RESECTION, AND IMPORTANTLY, HIGHLIGHT AREAS OF EXTRACAPSULAR EXTENSION OR IN-TRANSIT METASTASES. TO ACHIEVE BOTH GOALS, THOUGH, A TECHNOLOGY THAT IMPROVES CANCER CELL DETECTION BY AT LEAST 100-FOLD OVER CONVENTIONAL MEANS IS REQUIRED. THE HYPOTHESIS GUIDING THIS STUDY IS THAT ZWITTERIONIC CONTRAST AGENTS AND RADIOTRACERS, DEFINED AS MOLECULES WITH ELECTRICALLY-NEUTRAL AND GEOMETRICALLY-BALANCED ALTERNATING POSITIVE AND NEGATIVE CHARGES, WILL PROVIDE LOG-LEVEL IMPROVEMENTS IN MOLECULAR IMAGING. THIS HYPOTHESIS IS BASED ON OBSERVATIONS FROM OUR GROUP USING SMALL MOLECULE, PROTEIN, AND NANOPARTICLE SYSTEMS. IN EACH CASE, ZWITTERIONIC MOLECULES EXHIBITED EXTREMELY LOW NON-SPECIFIC BINDING TO NORMAL TISSUES AND ORGANS. AND, WHEN ENGINEERED TO EXHIBIT RAPID, RENAL- ONLY CLEARANCE, UNBOUND DOSE WAS ELIMINATED COMPLETELY FROM THE BODY, RESULTING IN HIGH SBR. THE FOCUS OF OUR STUDY IS PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA), A TYPE II MEMBRANE RECEPTOR TO WHICH WE HAVE PREVIOUSLY DEVELOPED HIGH AFFINITY (2 AND 9 NM) SMALL MOLECULE TARGETING LIGANDS CALLED GPI. WE WILL CREATE ZWITTERIONIC VERSIONS OF GPI THAT HAVE BOTH OPTICAL (800 NM NIR FLUORESCENCE) AND PET (DEFEROXAMINE CHELATION OF ZR-89) FUNCTIONAL GROUPS (ZWGPI). MATHEMATICAL MODELING OF ZWGPI'S PERFORMANCE IN VIVO REVEALS THAT THE COMBINATION OF CONSTITUTIVE ENDOCYTOSIS VIA PSMA, AND THE USE OF A LONG HALF-LIFE ISOTOPE, SUCH AS ZR-89, WILL RESULT IN SBRS 100-FOLD HIGHER THAN IS CURRENTLY POSSIBLE. OR SPECIFIC AIMS INCLUDE CHEMICAL OPTIMIZATION OF ZWGPI, IN VIVO VALIDATION, CGMP MANUFACTURE UNDER 21 CFR 211/212, AND A SET OF FIRST-IN-HUMAN TRIALS IN MEN UNDERGOING PROSTATE CANCER STAGING AND RESECTION. TO ACCOMPLISH THESE AMBITIOUS AIMS, WE HAVE ASSEMBLED AN INTERNATIONAL TEAM OF EXPERTS. WE ALSO LEVERAGE A UNIQUE INFRASTRUCTURE AT BIDMC. THE NEWLY OPENED TRANSLATIONAL CANCER IMAGING FACILITY (TCIF) IS CAPABLE OF MANUFACTURING IND-ELIGIBLE OPTICAL CONTRAST AGENTS AND PET RADIOTRACERS UNDER BOTH 21 CFR 211 AND 21 CFR 212 CGMP COMPLIANCE. OF SPECIAL NOTE, ZW800-1, THE ZWITTERIONIC NIR FLUOROPHORE ON WHICH THIS STUDY IS BASED, WAS ALSO MANUFACTURED IN THE TCIF AND HAS ALREADY BEEN THROUGH THE FDA IND PROCESS. THUS THE REGULATORY PATH FOR ZWGPI IS WELL DEFINED AT THE OUTSET AND BUDGETED APPROPRIATELY IN OUR APPLICATION. COMPLETION OF OUR SPECIFIC AIMS HAS THE POTENTIAL TO REVOLUTIONIZE PROSTATE CANCER CARE BY PROVIDING IMPROVED PET/MRI STAGING AND, IF THE CHOSEN DEFINITIVE TREATMENT IS SURGERY, REAL-TIME INTRAOPERATIVE GUIDANCE.
($10k)
10/1/22
Not listed
(PQC-5) ZWITTERIONIC NIR/ZR-89 AGENTS FOR PROSTATE CANCER STAGING AND TREATMENT
($97k)
7/30/19
Not listed
(PQC-5) ZWITTERIONIC NIR/ZR-89 AGENTS FOR PROSTATE CANCER STAGING AND TREATMENT
$0
5/6/19
Not listed
(PQC-5) ZWITTERIONIC NIR/ZR-89 AGENTS FOR PROSTATE CANCER STAGING AND TREATMENT
$0
4/25/19